MedTrace Logo

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

NCT00294437 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2012-05-01

No results posted yet for this study

Summary

To determine if therapy with Zometa® (zoledronic acid) 4mg will be effective in preventing the occurrence of bone metastases in prostate cancer patients at high risk of developing them. In addition, pain and analgesic scores and overall safety are to be evaluated throughout the study.

Conditions

Interventions

DRUG

Zometa

Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months

Sponsors & Collaborators

  • Central European Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Bobak Djavan, Prof · Univ. Klinik für Urologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2003-12-31
Completion
2007-11-30

Countries

  • Austria
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czechia
  • Estonia
  • Hungary
  • Lithuania
  • Montenegro
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Slovenia
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294437 on ClinicalTrials.gov